The study investigated whether the value of pan-immune inflammation (PIV) - a marker derived from routine blood tests - is useful in predicting the survival of patients after cardiopulmonary resuscitation. The study included 193 adult patients, of whom 85 (44.0%) died within the first 2 days and 108 (56.0%) survived for at least 72 hours. Although PIV was strongly correlated with other inflammatory markers (SII and SIRI), neither day 1 nor day 3 PIV values after ICU admission were independently associated with mortality. The analysis showed that PIV had a poor ability to distinguish between patients who would survive and those who would die. The authors concluded that although PIV is an inexpensive and readily available marker reflecting systemic inflammation, it did not provide independent prognostic information beyond the already used clinical severity scores. Future studies with more frequent sampling are needed to identify biomarkers that could better help predict outcomes in these patients.